Rita, Indo-Pacific bottlenose dolphin at Hong Kong's Ocean Park, dies at 24
A 24-year-old Indo-Pacific bottlenose dolphin named Rita has died at Hong Kong's Ocean Park after showing signs of fatigue and a loss of appetite.
The marine mammal had lived in the park for about 13 years after she was transferred from Tunisia. Investigations into her death are ongoing.
'Rita was a playful animal who got along well with her dolphin and human mates, and was a beloved animal ambassador living in the Marine Mammal Breeding and Research Centre next to the Ocean Park Veterinary Centre,' a park spokesman said.
Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.
She had refused to eat and showed signs of tiredness since Friday.
The park said that veterinarians performed thorough examinations and blood tests on the dolphin, which caretakers looked after around the clock.
But her health conditions worsened and she died on Sunday afternoon.
The park has conducted a necropsy to determine the cause of death, while further laboratory tests are under way.
The spokesman said that students had learned about and appreciated the natural behaviour and daily care of dolphins up close through guided tours, and were inspired to contribute to marine conservation.
'The park expresses its gratitude to Rita for conveying conservation messages to visitors. She will forever hold a special place in our hearts and memories,' he said.
Rita was transferred to Hong Kong from Friguia Park in Tunisia in November 2012, after the facility closed its dolphin show, according to Ceta-Base, an online database of captive-held cetaceans across the world.
She gave birth to a male calf named Rati in September 2015.
In 2021, Ocean Park announced that Milo, a seven-year-old female Indo-Pacific bottlenose dolphin, died after suffering acute haemorrhagic enteritis, or inflammation of the intestines.
More from South China Morning Post:
For the latest news from the South China Morning Post download our mobile app. Copyright 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 days ago
- The Star
Godiva ordered by Hong Kong govt to halt dark chocolate ice cream sale after bacteria find
Hong Kong authorities have ordered a branch of Belgian luxury chocolatier Godiva to halt the sale of its dark chocolate soft ice cream after a sample was found to contain a bacterial count 46 times above the legal limit. The Centre for Food Safety said on Thursday that the sample collected from the shop at Cityplaza in Tai Koo had 2.3 million bacteria per gram – 46 times higher than the legal limit of 50,000. 'The centre has informed the vendor involved of the irregularity and instructed it to stop selling and immediately dispose of the affected product,' a spokesman said. 'Prosecution will be instituted should there be sufficient evidence.' Under the Frozen Confections Regulation, those convicted of selling frozen confections with bacterial levels exceeding the legal limit face a maximum penalty of a fine of HK$10,000 (US$1,273) and three months' imprisonment. The spokesman said the centre had asked Godiva to carry out a thorough cleaning and disinfection. He added that the centre had also provided health education on food safety and hygiene to the vendor's representative and staff. The centre also noted that the total bacterial count exceeding the legal limit indicated unsatisfactory hygienic conditions, but that did not mean that consumption would lead to food poisoning. - SOUTH CHINA MORNING POST
New Straits Times
04-06-2025
- New Straits Times
#SHOWBIZ: 24-year-old Taiwanese influencer known for eating cosmetics dies
TAIPEI: In a tragic turn of events, Guava Beauty, a 24-year-old Taiwanese influencer known for eating beauty products or "make-up mukbang" videos, has died suddenly. Her death on May 24 has sparked widespread speculation on mainland Chinese social media, with many suggesting poisoning as a possible cause, the South China Morning Post reported. Her family announced the news of her passing in a statement posted on her social media account. It read: "It is with deep sorrow that we inform you that our treasured girl of beauty-product mukbangs, Guava Beauty, put down her brushes and flew off to start a new channel in heaven on May 24, 2025." "Thank you to everyone who ever liked, commented, and laughed with her. She truly cherished it all." The statement ended with, "Maybe when we meet again, she will be unboxing angel-exclusive make-up for her celestial mukbang." Guava Beauty, who had amassed over 12,000 followers on one social media platform, captivated her audience with a sweet, youthful image and creative content. Her signature videos featured her attempting to consume various beauty products, including lipstick, blush, face masks, and cotton pads. In a recent promotional clip for a jelly-like blush, she famously declared, "If you dare recommend it, I dare to eat it." The video showed her applying the blush before using a fork to eat it, describing it as "crispy, kind of like agar jelly," but ultimately, "terrible." While many fans were shocked by her content, others expressed concern that her videos might mislead viewers, particularly younger audiences, into believing that cosmetics were safe for consumption. The news of her death sent shockwaves across both mainland China and Taiwan, as evidenced by one user who commented, "I cannot believe it, but I know Guava Beauty will be the most beautiful beauty-mukbang angel in heaven." Mukbang (meaning eating broadcast) content is hugely popular in China and many other Asian countries.
Malaysian Reserve
31-05-2025
- Malaysian Reserve
Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
DA NANG, Vietnam, May 31, 2025 /PRNewswire/ — May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP). Under the theme 'Empowering the Potential of ctDNA-MRD,' 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice. 'While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation,' said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. 'Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology.' 'K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact' said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. 'This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region' A First-of-Its-Kind Gathering in Asia-Pacific Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics. The summit featured three key sessions shared by 16 esteemed experts K-CONNECT ACADEMIC Session: The Importance of ctDNA-MRD and CGP in Precision Oncology Unique Combination of Genomic & Transcriptomic Profiling with ctDNA-MRD Monitoring Key findings from Asia's First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors. K-CONNECT CASE SHARING Session ctDNA-MRD Applications & Real-World Case Sharing in Colorectal, Lung and Breast cancers. K-CONNECT NEXT LANDMARK Session Genetic Testing Guided Personalized Immunotherapy in Refractory Solid Tumors. Triad of Impact– A Multi-omic Solution to Advance Precision Oncology Innovation. Beyond an Event — Establishing a Platform for Ongoing Impact K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include: K-CONNECT Webinar Series – Ongoing expert-led case discussions Clinical Trials Collaboration – Cross-border partnerships with biopharma and research institutions Experience ctDNA-MRD Program – Hands-on implementation support for clinicians Knowledge Hub – A digital platform for APAC oncology insights Shaping the Future of Cancer Care K-CONNECT APAC 2025 solidified Gene Solutions' leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: MEDIA CONTACT: pr@
